Splitomicin is a cell-permeable lactone that acts as a selective inhibitor of Sir2p NAD+-dependent histone deacetylase activity. Splitomicin creates a conditional phenocopy of a sir2 deletion mutant in S. cerevisiae and sensitizes mammalian cells to a variety of DNA-damaging agents by abrogating Sir2p activity on p53. Splitomicin acts by either altering or blocking access to the acetylated histone binding pocket.
1. Bedalov, A., et al. 2001. Proc. Natl. Acad. Sci. USA 98: 15113-15118. PMID: 11752457
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.
Download SDS (MSDS)
Certificate of Analysis
Adobe Acrobat Reader is required to reliably view, print and comment on PDF documents
bvseo_sdk, java_sdk, bvseo-3.2.0
CLOUD, getContent, 71ms
bvseo-msg: The resource to the URL or file is currently unavailable.;
Rated 5 out of
ChapalamaduguChapalamadugu, KC. et al. (PubMed 25447406) found that Splitomicin caused inhibition of SiRT1 in H9C2 cells. This caused a decrease in SiRT1 and Kv1.5 expression, suggesting that SiRT1 may mediate Kv1.5 downregulation. -SCBT Publication Review
To place an order using RMB or to ship to mainland China, please visit www.scbio.cn
Create a new account
Email address already exists, please enter a new valid email address.
USE YOUR SOCIAL NETWORK
Create an account quickly and easily with your preferred social network account. You won't have to remember an extra name and password.
Creating an account with us makes your shopping experience much easier and faster. You can save favorites, save cart, check order status and speed through checkout with saved addresses, payment methods and more.